CTRI/2025/06/088792尚未招募不适用
Development, Validation and Reliability Testing of Comprehensive Scale addressing Physical, Psychosocial and Skill Related Fitness in School going Children.
Maharishi Markandeshwar Deemed to be University1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2025年6月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- Comprehensive Scale addressing Physical, Psychosocial and Skill Related Fitness (CS-PPSF)
研究概览
简要总结
This trial needs to assess Psychosocial health of School going children in India
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 10.00 Year(s) 至 16.00 Year(s)（—）
- 性别
- All
入选标准
- •Children with aged between 10 and 16 years Both boys and girls Children able to understand simple commands Children who are willing to participate.
排除标准
- •Systemic illness.
- •Musculoskeletal disorders Neurological disorders Psychological disorders Fracture in upper or lower extremity in past 6 months.
结局指标
主要结局
Comprehensive Scale addressing Physical, Psychosocial and Skill Related Fitness (CS-PPSF)
时间窗: BASELINE,2 DAYS
次要结局
未报告次要终点
研究者
Kanu Goyal
Phd Scholar
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A phase III, blinded, randomised, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life. - MeMuRu-OKA 044EUCTR2004-005263-19-DEGSK Biologicals944
未知
3 期
SUMIREJPRN-jRCT2080221041AstraZeneca
进行中（未招募）
不适用
Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administration of SKP-1052 versus immediate-release terbutaline and placebo tablets in stable Type 1 Diabetes Mellitus PatientsMedDRA version: 12.1Level: LLTClassification code 10012601Term: Diabetes mellitusMedDRA version: 12.1Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentMedDRA version: 12.1Level: LLTClassification code 10012610Term: Diabetes mellitus loss of controlType 1 Diabetes MellitusEUCTR2010-022513-26-DESkyePharma AG
已完成
3 期
SUMIRE (Symbicort in COPD patients)CTRI/2010/091/000153AstraZeneca AB120
尚未招募
4 期
A clinical study to evaluate the efficacy and safety of Nisha-Amalki capsules in preventing progression to Diabetes in patients with Pre-DiabetesCTRI/2018/08/015503PHARMANZA HERBAL PVT LTD